ORIGINAL RESEARCH article
Front. Microbiol.
Sec. Virology
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1611600
This article is part of the Research TopicViral Co-infections: Challenges and Therapeutic ApproachesView all articles
Antiviral Effects of Mogroside V Against Porcine Reproductive and Respiratory Syndrome Virus in Vitro
Provisionally accepted
Long Hua Liang1,2
Xiao Hui Huang1,2Guo Xi Qin1,3Xiao Yu Ma3Ri Jing He1,2Hong Peng Dai1,2Zhen Zhang1,2
Xiaogan Yang1,2
Xingwei Liang1,2*- 1Guangxi University, Nanning, China
- 2Guangxi Key Laboratory of Animal Breeding & Disease Control and Prevention, Guangxi University, Nanning, Guangxi, China., Guangxi,Nanning, China
- 3Guangxi Agricultural Reclamation Yongxin Livestock Group Jinguang Livestock Co., Ltd, Nanning, Guangxi 530042, China., Guangxi,Nanning, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Porcine reproductive and respiratory syndrome virus (PRRSV) infection has inflicted devastating impacts on the global swine industry, while current vaccines provide limited protection against this disease. Mogroside V (MV), a triterpenoid compound derived from Siraitia grosvenorii, exhibits diverse biological activities including antioxidant, anti-inflammatory, and anti-cancer properties, with the capacity to scavenge free radicals and mitigate oxidative stress. In this study, MV was administered to PRRSV-infected cells via three distinct treatment modalities. Our findings demonstrate that MV effectively blocks or suppresses infections caused by diverse PRRSV subtypes in porcine alveolar macrophages (PAMs) and Marc-145 cells. MV exhibited significant dosedependent antiviral efficacy, with viral titers and mRNA expression inhibited by over 90% at a concentration of 400μM. Comparative analysis further revealed substantial variations in antiviral efficacy among the different treatment protocols. Notably, PRRSV employs immune evasion mechanisms to suppress host innate immunity. MV not only directly inhibited PRRSV replication but also significantly upregulated the gene expression of immunomodulatory cytokines (IL-1, IL-2, IL-8, IL-18; P<0.05), suggesting a dual mechanism of antiviral action. These findings underscore the antiviral bioactivity of MV and highlight its potential as a novel therapeutic candidate for PRRSV intervention.
Keywords: PRRSV1, Mogroside V2, Antiviral action3, antioxidant4, Cytokines5
Received: 14 Apr 2025; Accepted: 12 Jun 2025.
Copyright: © 2025 Liang, Huang, Qin, Ma, He, Dai, Zhang, Yang and Liang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xingwei Liang, Guangxi University, Nanning, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.